Table 3.
Clinical Characteristics of Smoldering Multiple Myeloma with or without AL Amyloidosis
| *Amyloidosispos N=21 | †Amyloidosisneg N=15 | P | |
|---|---|---|---|
| Age≧65 (%) | 8 (38.0) | 4 (26.7) | 0.473 |
| Sex=Male (%) | 16 (76.1) | 10 (66.7) | 0.709 |
| ALP>187.5IU/L (%) | 3 (14.2) | 0 (0.0) | 0.250 |
| Severe hypoalbuminemia (%) | 9 (42.8) | 1 (6.7) | 0.024 |
| Higher LDH (%) | 4 (19.0) | 1 (6.7) | 0.376 |
| BNP≧700pg/mL (%) | 6 (28.5) | 0 (0.0) | 0.030 |
| Higher BMPC (%) | 5 (23.8) | 4 (26.7) | 1.000 |
| Affected light-chain types=λ (%) | 18 (85.7) | 8 (53.3) | 0.058 |
Note: The bold font represents statistical significance.
Abbreviations: *Amyloidosispos, smoldering multiple myeloma with amyloidosis; †Amyloidosisneg, smoldering multiple myeloma without amyloidosis; ALP, alkaline phosphatase; LDH, lactate dehydrogenase; BNP, brain natriuretic peptide; BMPC, bone marrow plasma cells ratio.